Viropharma Picovir Pre-Prescribing Raises Risk Management Issues
Executive Summary
Viropharma Picovir studies should address pre-prescribing issues, FDA's Antiviral Drugs Advisory Committee said at its March 19 meeting
You may also be interested in...
FDA Risk Cmte. Includes “Cooperative Agreement” Grantee Gardner
FDA Drug Safety & Risk Management Subcommittee member Jacqueline Gardner, PhD, is a former grantee of the agency's cooperative agreement program to provide active surveillance data for the Office of Drug Safety
FDA Risk Cmte. Includes “Cooperative Agreement” Grantee Gardner
FDA Drug Safety & Risk Management Subcommittee member Jacqueline Gardner, PhD, is a former grantee of the agency's cooperative agreement program to provide active surveillance data for the Office of Drug Safety
Viropharma Picovir Oral Contraceptive Study Data Expected This Summer
Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months